Author name: Leonardo Arias

El campo magnético de la Tierra es una de las barreras invisibles más importantes para la vida. Nos protege de la radiación solar, guía las brújulas y está profundamente ligado al funcionamiento interno del planeta. Sin embargo, a lo largo de la historia geo …

¿Qué nos hace específicamente humanos? Durante siglos la respuesta fue filosófica, pero hoy la genética ofrece pistas sorprendentes. No se trata solo de tener un “gen de la inteligencia” o del lenguaje, sino de una compleja combinación de genes, …

BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.

Durante décadas, la palabra cultura se reservó casi en exclusiva a los seres humanos. Se asociaba a conceptos como arte, lenguaje simbólico, tradiciones o normas sociales transmitidas de generación en generación. Sin embargo, en los últimos años, la i …

With inspections always on the table, LOTTE Biologics is pushing a proactive, quality first culture across its dual hubs in Syracuse and Songdo, backing its new single‑use ADC facility with rigorous training, self‑audits and real‑time regulatory surveillance.

After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who accelerates timelines and anticipates every manufacturing hurdle. Learn how AGC Biologics offers tailored cell line solutions for complex molecules.

As biotechs faced investors at the J.P. Morgan Healthcare Conference this week, they emphasized agreement with the FDA on clinical trial design and regulatory pathways to approval. Atara, meanwhile, lamented the agency’s “complete reversal of position” after its therapy for a rare surgical complication was rejected.

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting gene silencers to blood-brain barrier delivery platforms—is entering the pipeline to anchor future combination therapies.

The findings are “very depressing,” one commissioner said. Still, it’s a smaller sum than in 2025, thanks to the continued phase-in of a new risk adjustment model.

CEO Dave Rosa said a strong rollout for the da Vinci 5 surgical robot in 2025 exceeded expectations, with the system driving greater utilization than the earlier Xi model.